Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Clinical Trials

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: Pimasertib
Drug: Temsirolimus

First Posted Date: 2011-06-22

Last Posted Date: 2018-07-30

Lead Sponsor: EMD Serono

Target Recruit Count: 33

Registration Number: NCT01378377

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
For Recruiting Locations in the US contact US Medical Information in, Rockland, Massachusetts, United States

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Adult Solid Neoplasm

Interventions: Drug: Ixabepilone
Other: Pharmacological Study
Drug: Temsirolimus

First Posted Date: 2011-06-17

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01375829

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Phase 1

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Temsirolimus + Sorafenib

First Posted Date: 2011-04-13

Last Posted Date: 2016-11-15

Lead Sponsor: Philipps University Marburg Medical Center

Registration Number: NCT01335074

Locations: 🇩🇪
University Hospital Giessen and Marburg, Marburg, Germany

Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer

Not Applicable

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Drug: Temsirolimus
Drug: Cetuximab
Drug: Cisplatin
Device: Radiation Therapy

First Posted Date: 2011-03-30

Last Posted Date: 2025-05-02

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT01326468

Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Phase 2

Withdrawn

Conditions: Liver Neoplasms

Interventions: Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2

First Posted Date: 2011-01-24

Last Posted Date: 2013-07-04

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT01281943

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkins Lymphoma

Interventions: Drug: Velcade
Drug: Temsirolimus

First Posted Date: 2011-01-24

Last Posted Date: 2019-12-13

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 40

Registration Number: NCT01281917

Locations: 🇺🇸
Bellin Memorial Hospital, Inc, Green Bay, Wisconsin, United States
🇺🇸
Gunderson Lutheran Health System, La Crosse, Wisconsin, United States
🇺🇸
Aurora Baycare Medical Center-GreenBay, Green Bay, Wisconsin, United States

and more 15 locations

Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Drug: Bevacizumab
Drug: Temsirolimus

First Posted Date: 2010-12-21

Last Posted Date: 2017-02-14

Lead Sponsor: Hellenic Cooperative Oncology Group

Target Recruit Count: 39

Registration Number: NCT01264341

Locations: 🇬🇷
Agii Anargiri Cancer Hospital, 2nd Dept of Medical Oncology, Athens, Greece
🇬🇷
Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology, Athens, Greece
🇬🇷
Papageorgiou General Hospital, Thessaloniki, Greece

and more 5 locations

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Phase 2

Completed

Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Laryngeal Verrucous Carcinoma
Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Recurrent Oral Cavity Verrucous Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma
Recurrent Salivary Gland Carcinoma

Interventions: Biological: Cetuximab
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2010-12-08

Last Posted Date: 2017-03-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT01256385

Locations: 🇺🇸
Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇨🇳
Chinese University of Hong Kong-Prince of Wales Hospital, Shatin, Hong Kong, China

and more 21 locations